Ovation Science Expands its Distribution of DermSafe into Mexico to Assist in the Fight Against the Coronavirus (COVID-19)

Ovation Science (CSE OVAT)
Published on: June 23, 2020

Vancouver, British Columbia; Las Vegas, Nevada – (June 23, 2020) – Ovation Science Inc. (CSE: OVAT) (“Ovation” or the “Company”), announces it has expanded distribution of its DermSafe® hand sanitizer lotion to Mexico.  Ovation’s new distributor, Grupo Venta International, S.A. de C.V. (“Grupo Venta”), with corporate offices in Guadalajara, Mexico, have made their first purchase of over 10,000 bottles of DermSafe, which they will begin distributing through-out Mexico. DermSafe® is a pharmaceutical-grade hand sanitizer lotion that uses chlorhexidine gluconate; an ingredient used worldwide in hospitals as it has a proven ability to kill germs. DermSafe has been developed with patented Invisicare® technology, which binds the product to the hands and resists wash-off and rub-off.

Grupo Venta, founded in 1990, is a company dedicated to supplying the highest quality, cutting-edge surgical equipment, supplies, cosmetic and wellness products through-out Mexico. They have three distinct business units. With its forty-six sales representatives across the country, they target various medical specialties including over 3,000 dermatologists, 1,900 surgeons and other medical specialists and hospitals. Secondly they employ a B2B and B2C strategy which focuses on bringing post-surgical and dermatology products to be sold in doctors’ offices as well as retail and on their online portal called “Top Care Store”.  Thirdly, Grupo Venta utilizes a retail and online strategy for wellness products marketed by department stores, pharmacies and through various other online marketplaces in Mexico.  This opportunity with Grupo Venta provides the Company with the ability to expand its sales efforts of DermSafe hand sanitizer through an established medical distributor with a robust distribution network.

“We are thrilled that Grupo Venta has proceeded very quickly with their desire to make DermSafe available through-out Mexico through their medical and consumer distribution channels.  We knew they were excited to get onboard when over 80 sales representatives and staff participated in our virtual training. We were also impressed when they shortly after organized a physicians’ virtual training for this week,” said Terry Howlett, President of Ovation. “Doctors understand that alcohol hand sanitizers can have a devastating effect on your hands and that contact dermatitis caused by the alcohol can be very painful for people.”  He added, “Grupo Venta is well positioned in Mexico to sell DermSafe as they have an established distribution system to both medical professionals and consumers and they understand the need for a pharmaceutical-grade hand sanitizer like DermSafe.”

“We are pleased to be working with Ovation Science and to be able to provide DermSafe hand sanitizer to help protect the citizens of Mexico during this devastating COVID-19 pandemic. Adding DermSafe to our current COVID-19 product offering is a great fit as we interact with physicians and consumers across our country with other medical, surgical and aesthetic / wellness products,” said Ms. Gabriela González Alonso, Director General and C.E.O. of Grupo Venta. “As we have seen a surge of COVID-19 cases in Mexico recently, we are thankful that we can do our part by bringing high quality products such as DermSafe to the marketplace.”

For information about Ovation Science products visit https://ovationscience.com/products/.

Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease.    

To learn more about Ovation Science, please visit:

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including DermSafe, all made with patented Invisicare® skin delivery technology. The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales.  Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular there is no assurance that the Company’s DermSafe product will be licensed or approved for sale in Mexico, and that if approval is obtained that it will result in sales. Although DermSafe has been tested against other envelope viruses there is no assurance that it will kill or be as effective against COVID-19. In addition there is no assurance the Company’s level of sales will continue or will not be negatively impacted by increased competition and recovery from the coronavirus pandemic. Other examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: strategies, potential sales, distribution and manufacturing of the Company’s product as well as its effectiveness against COVID-19, the Company’s ability to receive regulatory approval outside of Canada. There are no guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control. Accordingly, readers should not place undue reliance on the forward-looking information. Ovation disclaims any obligation to revise or update any such forward-looking information to reflect future results, events or circumstances, except as required by law. 

Statements have not been evaluated by the Food and Drug Administration or Health Canada. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact:

FOR INVESTOR RELATIONS:

Sebastian Kunyz: [email protected]  Phone 604-684-6730 or 866-684-6730

FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:

Doreen McMorran: [email protected]  Phone:  604.283.0903 ext. 4

Cannabis Healthcare Life Science